The cure for osteoporosis to help victims of prostate cancer

In Europe, the expected approval of the use of new drugs for patients with prostate cancer. The drug protects the bones of the patient from injury.

Medicine denosumab   can help tens of thousands of patients prostate cancer Who are already receiving hormone therapy. Because it grows the risk of loss of bone mass, which increases the risk of fractures. And yet many of the thousands of victims of the disease necessarily go through hormone therapy.

Until recently, doctors prescribe to patients zoledronic acid, if the disease is threatening to touch bone. However, clinical studies have shown that denosumab   is more effective in preventing fractures, as its action lasts, on average, three and a half months longer than any other similar drugs.

Denosumab   It stimulates the immune system of patients prostate cancer By blocking the effect of a protein called RANK ligand-reducing activity of the cells which destroy bone. As a result, increases the density and strength of bone mass. The cost of treatment with this drug to patients is 1 UK pound per day (47 rubles). Medicine is moving together pharmaceutical companies Amgen and GlaxoSmithKline.

Back in 2010 denosumab has been approved by regulatory agencies in many European countries as a treatment for osteoporosis in women, as the drug significantly reduced the number of fractures of the spine and hips. Now the drug should be included in the category of cancer. It is expected that the greatest benefit from the use of denosumab received patients with advanced tumors.

Industry News

Go back to the main page